This clinical investigation is intended to evaluate the safety and effectiveness of Abbott’s AmplatzerTM AmuletTM Left Atrial Appendage (LAA) occluder device (“Amulet device”) compared to commercially available non-vitamin K antagonist oral anticoagulant (NOAC) drugs in patients with non-valvular atrial fibrillation (AF) who are at increased risk for ischemic stroke and who are tolerant of long-term NOAC therapy.
Articles
May 6, 2020
During these days of the pandemic, hospitals, physician offices and healthcare facilities continue to safely treat patients with non-COVID-19 emergencies and time-sensitive medical needs, especially those with acute and chronic conditions.